As of 2026-10-05, the EV/EBITDA ratio of Alpine Immune Sciences Inc (ALPN) is -87.88. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ALPN's latest enterprise value is 4,423.93 mil USD. ALPN's TTM EBITDA according to its financial statements is -50.34 mil USD. Dividing these 2 quantities gives us the above ALPN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.4x - 16.0x | 15.6x |
| Forward P/E multiples | 17.0x - 19.6x | 18.4x |
| Fair Price | (12.01) - (11.26) | (11.99) |
| Upside | -118.5% - -117.3% | -118.5% |
| Date | EV/EBITDA |